MedPlus Health Services Limited has successfully completed the allotment of 2,32,061 equity shares to eligible employees under its Employee Stock Option Plan 2021 (ESOP 2021) scheme. The Board of Directors approved this allotment on January 30, 2026, following the recommendation of the Nomination and Remuneration Committee.

Share Allotment Details

The allotment comprises equity shares with a face value of ₹2 each, fully paid up, issued to eligible employees of the company and its group companies. The shares were exercised at two distinct price levels, reflecting different grant tranches under the ESOP scheme.

Impact on Share Capital

The allotment has resulted in an increase in the company's paid-up share capital structure. The total issued shares have expanded from 11,98,22,581 to 12,00,54,642 equity shares.

Regulatory Compliance and Share Characteristics

The allotment was conducted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The newly issued equity shares carry the ISIN number INE804L01022 and will rank pari passu with existing equity shares, ensuring identical rights and privileges.

ESOP Scheme Background

The MedPlus Employee Stock Option Plan 2021 was previously filed with both BSE Limited and National Stock Exchange of India Limited on January 09, 2023. The scheme received in-principle approval with reference numbers BSE-DCS/IPO/PB/ESOP-IP/2664/2022-23 and NSE-NSE/LIST/34067. The distinctive numbers for the newly allotted shares range from 119822582 to 120054642, with no lock-in restrictions applicable to these shares.

The company has confirmed that detailed disclosures regarding this allotment are available on its official website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited for stakeholder reference.

MedPlus Health Services Limited has announced its unaudited financial results for the quarter ended December 31, 2025, showcasing strong operational performance and continued growth momentum. The company's Board of Directors approved the quarterly results at their meeting held on January 30, 2026.

Financial Performance Highlights

The company delivered impressive financial results for Q3FY26, with consolidated revenue from operations reaching ₹18,061.18 million compared to ₹15,614.46 million in Q3FY25, representing a robust growth of 15.67%. Net profit after tax increased significantly by 26.00% to ₹577.88 million from ₹458.70 million in the corresponding quarter of the previous year.

Profitability and Margin Expansion

The company demonstrated strong operational efficiency with EBITDA reaching ₹1.60 billion in Q3FY26 compared to ₹1.10 billion in the corresponding quarter of the previous year. The EBITDA margin expanded significantly to 8.78% from 6.83%, reflecting improved cost management and operational leverage.

Nine-Month Performance

For the nine-month period ended December 31, 2025, the company maintained its growth trajectory with revenue from operations of ₹50,280.81 million compared to ₹46,264.44 million in the corresponding period of FY25, marking an 8.68% increase. Net profit for the nine-month period stood at ₹1,556.33 million, up from ₹989.13 million in the previous year, representing a substantial growth of 57.35%.

Segment-wise Performance

The retail segment remained the primary revenue contributor, generating ₹17,733.70 million in Q3FY26 compared to ₹15,338.87 million in Q3FY25. The diagnostic services segment contributed ₹326.67 million in revenue, up from ₹274.67 million in the previous year. The retail segment also delivered strong profitability with segment results of ₹641.30 million compared to ₹536.61 million in Q3FY25.

Corporate Actions and Regulatory Updates

The Board approved the allotment of 2,32,061 equity shares under the MedPlus Employees Stock Option Plan 2021 to eligible employees. The company clarified that this allotment is not material in nature. The statutory auditors B S R and Co. have expressed an unmodified opinion in their Limited Review Report for both standalone and consolidated financial results.

Labour Code Impact

The company has assessed the impact of the four Labour Codes notified by the Government of India on November 21, 2025. For the consolidated results, MedPlus recorded an incremental non-recurring impact of ₹70.59 million as employee benefits expense. The company continues to monitor developments and will provide appropriate accounting treatment as needed.

Standalone Performance

On a standalone basis, the company reported revenue from operations of ₹2,230.01 million in Q3FY26 compared to ₹1,767.93 million in Q3FY25, representing growth of 26.13%. Standalone net profit increased to ₹165.76 million from ₹93.69 million, marking a significant improvement of 76.95%.